Off-campus UMass Amherst users: To download campus access dissertations, please use the following link to log into our proxy server with your UMass Amherst user name and password.

Non-UMass Amherst users: Please talk to your librarian about requesting this dissertation through interlibrary loan.

Dissertations that have an embargo placed on them will not be available to anyone until the embargo expires.

Author ORCID Identifier

0000-0003-0877-9058

AccessType

Campus-Only Access for Five (5) Years

Document Type

dissertation

Degree Name

Doctor of Philosophy (PhD)

Degree Program

Public Health

Year Degree Awarded

2022

Month Degree Awarded

September

First Advisor

Susan Hankinson

Second Advisor

Elizabeth Bertone-Johnson

Third Advisor

Jing Qian

Fourth Advisor

Zhenhua Liu

Subject Categories

Epidemiology | Public Health | Women's Health

Abstract

Endogenous hormones play a role in many health conditions that impact women. Estrogens increase breast cancer risk through estrogen receptor (ER) mediated pathway activation. Modifiable factors such as 25-hydroxyvitmain D (25(OH)D) may influence endogenous hormone levels, and incidence and survival of diseases such as breast cancer.

In Chapter 1, we conducted a prospective, nested case-control study among postmenopausal women using the Nurses’ Health Study (NHS), that included 371 cases with blood samples collected prior to breast cancer diagnosis and 731 matched controls. Estrogen pathway activity (EA) was assessed via a luciferase reporter assay using T47D-Kbluc human breast cancer cells. We assessed the contribution of EA to risk, independent of circulating estrone, estradiol, and estrone sulfate concentrations. Our study provides a first detailed assessment of a breast cancer cell line-based EA assay and postmenopausal breast cancer risk.

In Chapter 2, we examined the association between circulating 25(OH)D concentrations and breast cancer-specific and all-cause mortality among women with breast cancer. Our study population consisted of 1,312 invasive breast cancer survivors in the NHS and NHS2 cohorts. Women provided a blood sample in 1989-1990 and a second blood sample in 2000-2001 (NHS) or a blood sample in 1996-1999 (NHS2). Women were diagnosed with breast cancer after blood collection and followed until death or 2016 (NHS) or 2017 (NHS2).

In Chapter 3, we evaluated the association of 25(OH)D and vitamin D binding protein (DBP) with levels of several endogenous sex steroids and prolactin to provide insight into the potential biologic impact of 25(OH)D and DBP. We conducted a cross-sectional study among 1,625 premenopausal NHS2 women. We used 25(OH)D and DBP concentrations and menstrual cycle-timed sex hormones, all measured in plasma. Estrogen metabolite levels were measured in luteal phase urine samples.

In conclusion, our findings suggested (1) a positive association between EA and breast cancer risk, however, the association was substantially attenuated after accounting for levels of other estrogens, (2) higher pre-diagnostic vitamin D levels are associated with improved overall survival, but not breast cancer-specific survival, in women with breast cancer, and (3) little association of 25(OH)D or DBP with sex steroid hormones.

DOI

https://doi.org/10.7275/30929503

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Available for download on Friday, September 01, 2023

Share

COinS